Pembrolizumab for recurrent/metastatic head and neck cancer: equally promising for Asian patients?

被引：0
作者：
Ye, Wenda [1 ,2 ,3 ]
Schmitt, Nicole C. [1 ,4 ]
机构：
[1] NIDCD, Integrat Therapeut Program, Bethesda, MD USA
[2] NIH, Med Res Scholars Program, Bldg 10, Bethesda, MD 20892 USA
[3] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA
[4] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Bethesda, MD USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2019年 / 7卷
关键词：
SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; RECURRENT; NIVOLUMAB; PACIFIC; SAFETY;
D O I：
10.21037/atm.2019.01.46
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 13 条
[1]   The evolution of the epidemiological landscape of head and neck cancer in Italy: Is there evidence for an increase in the incidence of potentially HPV-related carcinomas? [J].
Boscolo-Rizzo, Paolo ;
Zorzi, Manuel ;
Del Mistro, Annarosa ;
Da Mosto, Maria Cristina ;
Tirelli, Giancarlo ;
Buzzoni, Carlotta ;
Rugge, Massimo ;
Polesel, Jerry ;
Guzzinati, Stefano .
PLOS ONE, 2018, 13 (02)
[2]   The enigmatic epidemiology of nasopharyngeal carcinoma [J].
Chang, Ellen T. ;
Adami, Hans-Olov .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (10) :1765-1777
[3]   Nasopharyngeal carcinoma [J].
Chua, Melvin L. K. ;
Wee, Joseph T. S. ;
Hui, Edwin P. ;
Chan, Anthony T. C. .
LANCET, 2016, 387 (10022) :1012-1024
[4]   Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck [J].
Ferris, R. L. ;
Blumenschein, G., Jr. ;
Fayette, J. ;
Guigay, J. ;
Colevas, A. D. ;
Licitra, L. ;
Harrington, K. ;
Kasper, S. ;
Vokes, E. E. ;
Even, C. ;
Worden, F. ;
Saba, N. F. ;
Iglesias Docampo, L. C. ;
Haddad, R. ;
Rordorf, T. ;
Kiyota, N. ;
Tahara, M. ;
Monga, M. ;
Lynch, M. ;
Geese, W. J. ;
Kopit, J. ;
Shaw, J. W. ;
Gillison, M. L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1856-1867
[5]  
Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI [10.1001/jamaoncol.2016.5688, 10.1001/jamaoncol.2018.2706]
[6]   Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study [J].
Hsu, Chiun ;
Lee, Se-Hoon ;
Ejadi, Samuel ;
Even, Caroline ;
Cohen, Roger B. ;
Le Tourneau, Christophe ;
Mehnert, Janice M. ;
Algazi, Alain ;
van Brummelen, Emilie M. J. ;
Saraf, Sanatan ;
Thanigaimani, Pradeep ;
Cheng, Jonathan D. ;
Hansen, Aaron R. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) :4050-+
[7]   A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141 [J].
Kiyota, Naomi ;
Hasegawa, Yasuhisa ;
Takahashi, Shunji ;
Yokota, Tomoya ;
Yen, Chia-Jui ;
Iwae, Shigemichi ;
Shimizu, Yasushi ;
Hong, Ruey-Long ;
Goto, Masahiro ;
Kang, Jin-Hyoung ;
Li, Wing Sum Kenneth ;
Ferris, Robert L. ;
Gillison, Maura ;
Namba, Yoshinobu ;
Monga, Manish ;
Lynch, Mark ;
Tahara, Makoto .
ORAL ONCOLOGY, 2017, 73 :138-146
[8]   Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study [J].
Nanda, Rita ;
Chow, Laura Q. M. ;
Dees, E. Claire ;
Berger, Raanan ;
Gupta, Shilpa ;
Geva, Ravit ;
Pusztai, Lajos ;
Pathiraja, Kumudu ;
Aktan, Gursel ;
Cheng, Jonathan D. ;
Karantza, Vassiliki ;
Buisseret, Laurence .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (21) :2460-+
[9]   Global cancer statistics, 2002 [J].
Parkin, DM ;
Bray, F ;
Ferlay, J ;
Pisani, P .
CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (02) :74-108
[10]   Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial [J].
Seiwert, Tanguy Y. ;
Burtness, Barbara ;
Mehra, Ranee ;
Weiss, Jared ;
Berger, Raanan ;
Eder, Joseph Paul ;
Heath, Karl ;
McClanahan, Terrill ;
Lunceford, Jared ;
Gause, Christine ;
Cheng, Jonathan D. ;
Chow, Laura Q. .
LANCET ONCOLOGY, 2016, 17 (07) :956-965
12